Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

Jan 1, 1962·Archiv für Psychiatrie und Nervenkrankheiten, vereinigt mit Zeitschrift für die gesamte Neurologie und Psychiatrie·W Birkmayer, Oleh Hornykiewicz

Description of Parkinson's disease as a clinical syndrome

Jul 9, 2003·Annals of the New York Academy of Sciences·Stanley Fahn

SOME PHARMACOLOGICAL PROPERTIES OF THIOPROPERAZINE AND THEIR MODIFICATION BY ANTI-PARKINSONIAN DRUGS

Apr 1, 1964·British Journal of Pharmacology and Chemotherapy·G B LESLIE, D R MAXWELL

Tremor-related activity of neurons in the 'motor' thalamus: changes in firing rate and pattern in the MPTP vervet model of parkinsonism

Jun 20, 2003·The European Journal of Neuroscience·D GuehlL Tremblay

Parkinson's disease management strategies

Feb 10, 2006·Expert Review of Neurotherapeutics·Alex Rajput, Ali H Rajput

Considering the causes of RLS

Aug 26, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J W Winkelman

Targeting the dopamine D2 receptor in schizophrenia

Jul 20, 2006·Expert Opinion on Therapeutic Targets·Philip Seeman

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery

Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Mohammad S AlavijehAlan M Palmer

Failures and successes of clinical trials for Parkinson disease treatments

Dec 24, 2005·Retina·Ted M Dawson

AUTONOMIC REGULATION DISTURBANCES IN PATIENTS RECOVERING FROM ENCEPHALITIS

Oct 2, 1964·Acta Neurovegetativa·W Birkmayer

An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats

May 16, 2006·Amino Acids·Krystyna OssowskaA Pilc

Self-amplification of nigral degeneration in Parkinson's disease: a hypothesis

Oct 22, 2008·The International Journal of Neuroscience·Ilya D Ionov

Parkinson's disease: unresolved issues

Jan 8, 2009·Annals of Neurology·C Warren Olanow, Matthew B Stern

Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats

Oct 29, 2005·Journal of Neuropathology and Experimental Neurology·Véronique Sgambato-FaureFrançois Berger

Noggin enhances dopamine neuron production from human embryonic stem cells and improves behavioral outcome after transplantation into Parkinsonian rats

Sep 6, 2008·Stem Cells·Shunmei ChibaC R Freed

Methamphetamine fails to alter the noradrenergic integrity of the heart

Nov 11, 2008·Annals of the New York Academy of Sciences·Riccardo RuffoliF Fornai

Levodopa for the treatment of Parkinson's disease

Dec 5, 2008·The New England Journal of Medicine·Peter A Lewitt

Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances

Aug 28, 2009·Journal of Neural Transmission·V PérezJ Kulisevsky

Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine

Feb 23, 2010·PloS One·Katsuaki SuzukiNorio Mori

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management

Jun 6, 2009·Expert Review of Neurotherapeutics·Angelo Antonini, Eduardo Tolosa

Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease

Jul 19, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Kathleen M ShannonJeffrey H Kordower

Dopamine uptake in the substantia nigra and striatum in the presymptomatic and early symptomatic stages in parkinsonian mice

Jan 12, 2011·Doklady Biological Sciences : Proceedings of the Academy of Sciences of the USSR, Biological Sciences Sections·G R KhakimovaM V Ugryumov

Manganese and Parkinson's disease: a critical review and new findings

Nov 30, 2011·Ciência & saúde coletiva·Tomás R Guilarte

Less than perfect divorces: dysregulated mitochondrial fission and neurodegeneration

Dec 20, 2011·Acta Neuropathologica·Björn OettinghausStephan Frank

Arvid Carlsson: an early pioneer in translational medicine

Apr 7, 2010·Science Translational Medicine·Julie K Andersen

Striatal mechanisms underlying movement, reinforcement, and punishment

Jun 13, 2012·Physiology·Alexxai V Kravitz, Anatol C Kreitzer

Importance of the brain Angiotensin system in Parkinson's disease

Dec 6, 2012·Parkinson's Disease·John W Wright, Joseph W Harding

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease

Jun 22, 2013·Journal of Neurochemistry·David S GoldsteinYehonatan Sharabi

Removing the blinkers: moving beyond striatal dopamine in Parkinson's disease

May 21, 2013·Journal of Neurochemistry·Karen L Eskow Jaunarajs, David G Standaert

Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms

Oct 6, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Christian PiflOleh Hornykiewicz

L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

May 24, 2012·The Journal of Pharmacology and Experimental Therapeutics·Philippe HuotJonathan M Brotchie

Involvement of endocytosis and alternative splicing in the formation of the pathological process in the early stages of Parkinson's disease

May 8, 2014·BioMed Research International·Anelya Kh AlievaPetr A Slominsky

Vesicular integrity in Parkinson's disease

May 22, 2013·Current Neurology and Neuroscience Reports·Shawn P AlterGary W Miller

History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia

Jan 18, 2013·Journal of the History of the Neurosciences·Bertha K Madras

A possible pathophysiological role of tyrosine hydroxylase in Parkinson's disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer

May 31, 2012·Journal of Neural Transmission·Akira NakashimaT Nagatsu

Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells

May 29, 2015·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Hugo GonzálezRodrigo Pacheco

Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease

May 21, 2014·Neurotoxicity Research·Jolanta KoniecznyElzbieta Lorenc-Koci

Designer receptors: therapeutic adjuncts to cell replacement therapy in Parkinson's disease

Jun 18, 2014·The Journal of Clinical Investigation·Elena M Vazey, Gary Aston-Jones

Monoamine reuptake inhibitors in Parkinson's disease

Mar 27, 2015·Parkinson's Disease·Philippe HuotJonathan M Brotchie

Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects

Aug 6, 2016·Journal of Neural Transmission·T Nagatsu, I Nagatsu

Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr

Dec 10, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Andrew J LeesC Warren Olanow

Theodore L. Sourkes PhD, FRSC, OC (February 21, 1919-January 17, 2015)

Mar 2, 2016·Journal of the History of the Neurosciences·Paul Foley

199 years of Parkinson disease - what have we learned and what is the path to the future?

Sep 2, 2016·Journal of Neurochemistry·Jörg B SchulzJohn Hardy

L-DOPA

Mar 12, 2017·Journal of Parkinson's Disease·Oleh Hornykiewicz

Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications

Oct 16, 2016·The European Journal of Neuroscience·Harald SitteOleh Hornykiewicz

A review of presented mathematical models in Parkinson's disease: black- and gray-box models

Nov 8, 2015·Medical & Biological Engineering & Computing·Yashar Sarbaz, Hakimeh Pourakbari

Milestones of Parkinson's Disease Research: 200 Years of History and Beyond

Sep 13, 2017·Neuroscience Bulletin·Song Li, Weidong Le

Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease

Jan 16, 2019·Journal of Neural Transmission·Fanni F GeiblWolfgang H Oertel

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease

Sep 14, 2018·Frontiers in Neurology·Muthuraman MuthuramanSergiu Groppa

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease

May 22, 2019·Scientific Reports·Takuya UeharaHideki Mochizuki

Advances in Parkinson's Disease: 200 Years Later

Jan 9, 2019·Frontiers in Neuroanatomy·Natalia López-González Del ReyJavier Blesa

Dopamine Receptor D3 Expression Is Altered in CD4+ T-Cells From Parkinson's Disease Patients and Its Pharmacologic Inhibition Attenuates the Motor Impairment in a Mouse Model

May 24, 2019·Frontiers in Immunology·Daniela ElguetaRodrigo Pacheco

Dopamine in psychiatry: a historical perspective

Feb 14, 2019·Journal of Neural Transmission·Paul Foley

Altered growth hormone release in Huntington's chorea

Mar 1, 1976·Journal of Neurology, Neurosurgery, and Psychiatry·H J KeoghW R Sulaiman

Serotonin metabolism with idiopathic grand mal seizures

Dec 22, 1978·Journal of Neurology·D R MatzG G Brune

Venezuelan equine encephalomyelitis virus infection: effect on monoamine metabolism of mouse brain

Oct 1, 1975·Journal of Neurochemistry·E BonillaH Hernandez

Malassezia and Parkinson's Disease

Aug 10, 2019·Frontiers in Neurology·Martin LaurenceFrédéric Calon

Combination therapy of extrapyramidal disease with trihexyphenidyl and L-dopa: an electromyographic study with specific reference to tremor

Jan 1, 1979·The Journal of International Medical Research·H Hökendorf

Motor responses to sudden limb displacements in primates with specific CNS lesions and in human patients with motor system disorders

Aug 1, 1975·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·R G Lee, W G Tatton

Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease

Feb 1, 1992·Journal of Neurochemistry·Stephen J KishOleh Hornykiewicz

Parkinsonism and levodopa: a five-year experience

Nov 1, 1976·Journal of Clinical Pharmacology·P Delaney, J Fermaglich

Effect of L-dopa administration to fine structures of brain, heart and kidney in rats, with special reference to appearance of microvascular thrombosis and its pathological significance

Jan 1, 1975·Folia Psychiatrica Et Neurologica Japonica·M Takeichi

Selective increase of iron in substantia nigra zona compacta of parkinsonian brains

Mar 1, 1991·Journal of Neurochemistry·E SoficMoussa B H Youdim

Biochemical effects of psychotropic drugs in central nervous system (author's transl)

Jun 15, 1979·Klinische Wochenschrift·M Karobath

Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

Jan 1, 1988·Journal of Neural Transmission·E SoficMoussa B H Youdim

Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease

Mar 1, 1988·Acta Neurologica Scandinavica·J TedroffB Långström

On the effect of amantadine on ATP content and ATPase activity in brain and blood of rats

Apr 15, 1974·Experientia·V A Velkov

The biochemistry of catecholamines in relation to Parkinson's disease

May 1, 1971·Australian and New Zealand Journal of Medicine·H Hinterberger

The hypothalamus in Parkinson disease

Jun 1, 1987·Italian Journal of Neurological Sciences·R SandykC R Bamford

Long-term treatment with L-DOPA in a case of torsion dystonia (authors transl)

Jan 1, 1975·Journal of Neurology·W Winkelmann

Membrane properties of identified mesencephalic dopamine neurons in primary dissociated cell culture

Aug 1, 1992·Synapse·L A Chiodo, G Kapatos

Mn2+-stimulated ATPase in rat brain

Apr 1, 1983·Neurochemical Research·J D DohertyE G Trams

The effect of haloperidol on the urinary excretion of dopamine, homovanillic and vanilmandelic acids in schizophrenics

Jun 1, 1965·Psychopharmacologia·A Bruno, A Allegranza

Amine metabolites in the cerebrospinal fluid of patients with disseminated sclerosis

Jun 1, 1974·Journal of Neurology, Neurosurgery, and Psychiatry·L E ClaveriaB D Kantamaneni

Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method

Apr 1, 1984·Acta Neurologica Scandinavica·M A MenaJ G de Yébenes

Normal plasma dopamine-beta-hydroxylase in non-treated and treated Parkinson patients

Apr 1, 1981·Acta Neurologica Scandinavica·M MarkianosC Sfagos

DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness

Jan 1, 1983·Journal of Neural Transmission·W BirkmayerP Riederer

The investigation of homovanillic acid in the human brain and its correlation to senile dementia

May 1, 1969·The British Journal of Psychiatry : the Journal of Mental Science·C G GottfriesB E Roos

Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals (author's transl)

Jan 1, 1981·Archiv für Psychiatrie und Nervenkrankheiten·G SchneiderH R von Wedel

Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls

Jan 1, 1992·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·P HartikainenP J Riekkinen

Uptake and loss of 14 C-dopamine by platelets from children with infantile autism

Jan 1, 1972·Journal of Autism and Childhood Schizophrenia·D J Boullin, R A O'Brien

Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease

Jan 1, 1993·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·L Rioux, J N Joyce

Urinary noradrenaline and serotonin metabolites in drug-free Parkinson patients and the effect of L-dopa treatment

Aug 1, 1982·Acta Neurologica Scandinavica·M MarkianosE Bistolaki

Stereotaxic mapping of the monoamine pathways in the rat brain

Jan 1, 1971·Acta Physiologica Scandinavica. Supplementum·U Ungerstedt

The trained circling rat and in vivo electrochemistry: a behavioral model and a measurement method to study the dynamic role of dopamine in movement

Jan 1, 1986·Annals of the New York Academy of Sciences·C R Freed

Electrophysiological analysis of the effects of L-dopa on the reciprocal corticothalamic projections in the squirrel monkey. I. Iatrogenic coma and disinhibition of medial thalamic neurons

Jan 1, 1974·Journal of Neural Transmission·T L FrigyesiR Schwartz

Effect on the monoamine-metabolism of the mouse brain by experimental Herpes simplex infection

Jul 15, 1968·Experientia·E Lycke, B E Roos

Brain acetylcholinesterase in Parkinson's disease

Jan 1, 1973·Acta Neurologica Scandinavica·U K RinneH Laaksonen

Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease

Mar 19, 1973·Archiv für Psychiatrie und Nervenkrankheiten·E SchneiderH Maxion

Catecholamines

Sep 16, 1965·The New England Journal of Medicine·R J Wurtman

Determination of 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and homovanillic acid in brain tissue from an autopsy material

Jan 1, 1974·Acta Psychiatrica Scandinavica·C G GottfriesB Winblad

Influence of L-DOPA on night sleep in parkinsonian patients

Jan 1, 1972·Archiv für Psychiatrie und Nervenkrankheiten·K KendelH Zimmermann

Brain acetylcholine and cholinesterase: effect of phenothiazines and physostigmine interaction in rats

Jul 1, 1974·Journal of Neurochemistry·V H Sethy, M H Van Woert

The antiadrenaline activity of some phenothiazine derivatives

Oct 1, 1965·British Journal of Pharmacology and Chemotherapy·R A Webster

Homovanillic acid in the cerebrospinal fluid of Parkinsonian patients

Feb 1, 1983·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·L CunhaR Amaral

Amine precursor amino acid therapy: from neurochemical basis to clinical aspects

Feb 1, 1996·Neurochemical Research·T Nakajima

Dopaminergic modulation of visual sensitivity in man

Jan 1, 1993·Fundamental & Clinical Pharmacology·G MassonO Blin

Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism

Sep 1, 1969·Journal of Neurochemistry·C G GottfriesB E Roos

ERP indices of auditory selective attention in aging and Parkinson's disease

Jul 1, 1995·Psychophysiology·F KarayanidisP T Michie

Lingual-facial-buccal movements in the elderly. I. Pathophysiology and treatment

Jul 1, 1973·Journal of the American Geriatrics Society·W J Weiner, H L Klawans

Reversal by levodopa of cholinergic hypersensitivity in Parkinson's disease

Feb 25, 1971·The New England Journal of Medicine·M I Weintraub, M H Van Woert

Effect of 3,4-dimethoxyphenylethylamine injections upon dopamine metabolism in rats and dogs

Jul 15, 1967·Experientia·A BarbeauR Elie

Amine precursor therapy: manipulation of brain amine activity with precursor amino acid

Dec 31, 1997·Psychiatry and Clinical Neurosciences·T Nakajima

An in vivo comparison of the capacity of striatal versus extrastriatal brain regions to form dopamine from exogenously administered L-dopa

Jan 1, 1996·Journal of Neural Transmission·T BrannanM D Yahr

Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease

Nov 11, 1998·Nature Medicine·A L BrownellO Isacson

Striatal bradykinesia alleviated by intracaudate injection of L-dopa

Jan 15, 1968·Experientia·E A SpiegelD Zivanovic

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

Feb 15, 1996·Nature·Bruno GirosM G Caron

Fetal tissue transplantation [correction of transplanation] in Parkinson's disease

Sep 2, 1998·Current Opinion in Neurology·S TabbalS Frucht

Prospects of glutamate antagonists in the therapy of Parkinson's disease

Apr 2, 1998·Fundamental & Clinical Pharmacology·F Blandini, J T Greenamyre

Modification of Parkinsonism--chronic treatment with L-dopa

Feb 13, 1969·The New England Journal of Medicine·G C CotziasR Gellene

Pallidal stimulation: an alternative to pallidotomy?

Nov 5, 1997·Journal of Neurosurgery·V M TronnierS Steinvorth

Therapeutic advances in idiopathic Parkinsonism

Jan 5, 2001·Expert Opinion on Investigational Drugs·S L Shefrin

Pharmacological treatments of Parkinson's disease

Mar 10, 2001·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·M NomotoS Kaseda

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats

Feb 1, 2003·Journal of Neurochemistry·Günter U HöglingerEtienne C Hirsch

Trichloroethylene and parkinsonism: a human and experimental observation

Aug 24, 1999·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·D GuehlC E Gross

Dopamine miracle: from brain homogenate to dopamine replacement

Jul 12, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Oleh Hornykiewicz

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man

Jan 1, 1996·Journal of Neural Transmission·Manfred Gerlach, P Riederer

Paper chromatographic studies on the urine of schizophrenics and healthy subjects before and after DOPA administration

Jan 1, 1962·Psychopharmacologia·H LENZ

Neuroprotection for Parkinson's disease: a new approach for a new millennium

Jan 5, 2002·Expert Opinion on Investigational Drugs·B Drukarch, F L van Muiswinkel

DISTRIBUTION OF HOMOVANILLIC ACID IN THE HUMAN BRAIN

Nov 7, 1964·Nature·H Bernheimer

High-frequency stimulation of the subthalamic nucleus enhances striatal dopamine release and metabolism in rats

Apr 16, 2003·Journal of Neurochemistry·Wassilios MeissnerAndreas Kupsch

A half-century of neurotransmitter research: impact on neurology and psychiatry (Nobel lecture)

Feb 6, 2002·Chembiochem : a European Journal of Chemical Biology·A Carlsson

Muscarinic m1 and m2 receptor proteins in local circuit and projection neurons of the primate striatum: anatomical evidence for cholinergic modulation of glutamatergic prefronto-striatal pathways

May 9, 2001·The Journal of Comparative Neurology·A A AlcantaraP S Goldman-Rakic

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

Apr 30, 2002·Clinical Pharmacokinetics·Dirk DeleuYolande Hanssens

Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol

Feb 22, 2005·Journal of Neuroscience Research·Myreille D'AstousThérèse Di Paolo

SIDE-EFFECTS OF TREATMENT WITH PHENOTHIAZINE PREPARATIONS

Jan 1, 1965·Nordisk psykiatrisk tidsskrift. Nordic journal of psychiatry·A Faurbye

A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease?

Sep 30, 2005·The European Journal of Neuroscience·Krystyna OssowskaS Wolfarth

Imaging in cell-based therapy for neurodegenerative diseases

Nov 4, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Deniz KirikPhilippe Hantraye

Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany

Feb 25, 2005·Journal of Neurology·Wassilios MeissnerAndreas Kupsch

Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis

May 25, 2006·Cell Transplantation·Paul M CarveyMary B Newman

Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease

Nov 15, 2006·The European Journal of Neuroscience·Rebecca E ColebrookePiers C Emson

Catechol-O-methyltransferase and its inhibitors in Parkinson's disease

Sep 27, 2007·CNS Drug Reviews·Maria João BonifácioPatrício Soares-da-Silva

Parkinson's disease-like syndrome in rats induced by 2,9-dimethyl-beta-carbolinium ion, a beta-carboline occurring in the human brain

Aug 31, 2006·Behavioural Pharmacology·Elzbieta Lorenc-KociKrystyna Ossowska

Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity

Jul 10, 2002·Annals of the New York Academy of Sciences·G BattagliaF Fornai

Central dopamine deficiency in pure autonomic failure

Mar 26, 2008·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·David S GoldsteinAlexander O Vortmeyer

Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism

Feb 8, 2008·Proceedings of the National Academy of Sciences of the United States of America·Xiaoqun ZhangPer Svenningsson

On the effects of apomorphine in mammals and frogs

Aug 17, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Klaus Kuschinsky

Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats

Jun 6, 2008·Journal of Neural Transmission·Concepcio MarinMerce Bonastre

Neuroscience: the molecular wake-up call

May 25, 2007·Nature·Alison Abbott

Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease

Jun 4, 2010·Expert Review of Neurotherapeutics·W Michael CaudleJing Zhang

The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease

Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Anthony H V Schapira

Dopamine D₁ and D₂ receptor subtypes functional regulation in corpus striatum of unilateral rotenone lesioned Parkinson's rat model: effect of serotonin, dopamine and norepinephrine

Oct 5, 2010·Neurological Research·Jes PaulC S Paulose

Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats

Jul 29, 2009·Psychopharmacology·Anna JiménezConcepcio Marin

Identification of proteins in human substantia nigra

May 1, 2008·Proteomics. Clinical Applications·Efstathia KitsouJing Zhang

Milestones in research on the pathophysiology of Parkinson's disease

Jun 1, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Thomas WichmannJose A Obeso

Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa

Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yoland SmithMahlon R DeLong

Dopamine agonists and pathologic behaviors

May 9, 2012·Parkinson's Disease·Brendan J KelleyPeter Chiu

Glycogen synthase kinase 3β and its phosphorylated form (Y216) in the paraquat-induced model of parkinsonism

Feb 10, 2010·Neurotoxicity Research·Martyna SonginKrystyna Ossowska

Role of serotonin in central dopamine dysfunction

Jun 19, 2010·CNS Neuroscience & Therapeutics·Giuseppe Di GiovanniVincenzo Di Matteo

A brief history of levodopa

Nov 26, 2010·Journal of Neurology·Oleh Hornykiewicz

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

Jan 16, 2013·Pharmacological Reviews·Philippe HuotJonathan M Brotchie

Contributions to the field of neurotransmitters by Japanese scientists, and reflections on my own research

Mar 1, 2007·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Masanori Otsuka

Presynaptic dopaminergic function: implications for understanding treatment response in psychosis

Jun 13, 2014·CNS Drugs·I Bonoldi, O D Howes

Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia

Apr 29, 2014·Cerebral Cortex·Michel EngelnPierre-Olivier Fernagut

Basic science in Parkinson's disease: its impact on clinical practice

May 13, 2011·Journal of Neurology·Jörg B SchulzAlbert Ludolph

Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease

Aug 22, 2012·Journal of Neurochemistry·David S GoldsteinYehonatan Sharabi

Walther Birkmayer, Co-describer of L-Dopa, and his Nazi connections: victim or perpetrator?

Apr 5, 2014·Journal of the History of the Neurosciences·Herwig Czech, Lawrence A Zeidman

L-DOPA and graft-induced dyskinesia: different treatment, same story?

Jul 6, 2013·Experimental Biology and Medicine·Ludivine S Breger, Emma L Lane

A review of current and novel levodopa formulations for the treatment of Parkinson's disease

Feb 20, 2016·Therapeutic Delivery·Joohi Jimenez-Shahed

Early prenatal exposure to MPTP does not affect nigrostrial neurons in macaque monkey

Nov 20, 2015·Synapse·Mathieu BourdenxE Bezard

Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease

May 22, 2016·Journal of Neurochemistry·Daniela Maria Vogt WeisenhornWolfgang Wurst

Dopamine D1/D5 receptors mediate informational saliency that promotes persistent hippocampal long-term plasticity

Nov 28, 2012·Cerebral Cortex·Niels Hansen, Denise Manahan-Vaughan

Gene expression of proteins of the vesicle cycle in dopaminergic neurons in modeling of Parkinson's disease

Jul 16, 2016·Doklady. Biochemistry and Biophysics·E R Mingazov, M V Ugrumov

Revision of the classical dopamine D2 agonist pharmacophore based on an integrated medicinal chemistry, homology modelling and computational docking approach

Jul 25, 2014·Neurochemical Research·N Krogsgaard-LarsenT Balle

Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies

Mar 28, 2012·Brain : a Journal of Neurology·David S GoldsteinYehonatan Sharabi

An order in Lewy body disorders: Retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal/multifocal Lewy body disease

Nov 20, 2016·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Toshiki Uchihara

Circadian Clock Protein Content and Daily Rhythm of Locomotor Activity Are Altered after Chronic Exposure to Lead in Rat

Oct 4, 2017·Frontiers in Behavioral Neuroscience·Mariam SabbarNouria Lakhdar-Ghazal

Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano-secondary ion mass spectrometry

Apr 29, 2016·Journal of Neurochemistry·Antje BiesemeierUlrich Schraermeyer

Non-Motor Symptoms of Parkinson's Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients

Apr 20, 2018·Frontiers in Neurology·Houyam TibarWafa Regragui

Vulnerability of the mesencephalic dopaminergic neurons of the human neonate to prolonged perinatal hypoxia: an immunohistochemical study of tyrosine hydroxylase expression in autopsy material

Mar 14, 2013·Journal of Neuropathology and Experimental Neurology·Marianna A PagidaM T Panayotacopoulou

Historical and cross-cultural perspectives on Parkinson's disease

May 9, 2018·Journal of Complementary & Integrative Medicine·Lee Xenakis Blonder

Monitoring the Level of 14 C-Labelled Selegiline Following Oral Administration

Jun 2, 2017·The Open Medicinal Chemistry Journal·Huba KalászErnest Adeghate

Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease

Mar 9, 2018·Cell and Tissue Research·Hana YouJean-Christophe Corvol

Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses

May 28, 2019·Frontiers in Neuroscience·Xu-Qiao Chen, William C Mobley

The origins and early history of neurochemistry and its societies

Jul 30, 2019·Journal of Neurochemistry·Anne I BoullernePhilip M Beart

Gait Analysis for Early Detection of Motor Symptoms in the 6-OHDA Rat Model of Parkinson's Disease

Mar 22, 2018·Frontiers in Behavioral Neuroscience·Jordi BoixBronwen Connor

Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man

Sep 29, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Ali H Rajput, Stephen J Kish

Regional distribution of monoamines and their metabolites in the human brain

Apr 1, 1978·Journal of Neurochemistry·A V MackayP Davies

Monoamine acid metabolites in ventricular CSF of patients with brain tumours

Jan 1, 1976·Acta neurochirurgica·S R BareggiP L Morselli

Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases

Jul 24, 2019·JCI Insight·David S GoldsteinYehonatan Sharabi

Post-mortem stability of dopamine, glutamate decarboxylase and choline acetyltransferase in the mouse brain under conditions simulating the handling of human autopsy material

Jul 1, 1978·Journal of Neurochemistry·E G Spokes, D J Koch

Dopamine analogous 1,2,3,4-tetrahydro-beta-carbolines (author's transl)

Jan 1, 1978·Archiv der Pharmazie·K RehseR Horowski

Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in-vitro and in-vivo in mouse brain

Jan 1, 1989·The Journal of Pharmacy and Pharmacology·T YokoyamaN Iwata

The coincidence of schizophrenia and Parkinsonism: some neurochemical implications

May 1, 1976·Psychological Medicine·T J CrowH A McClelleand

Lewy bodies in parkinsonism share components with intraneuronal protein bodies of normal brains

Jan 1, 1991·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·M R IssidoridesM D Yahr

The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil

Jan 1, 1975·Journal of Neural Transmission·W BirkmayerW Linauer

Dopa resorption and dopamin estimation in blood of patients with Parkinson's disease (author's transl)

Jan 1, 1974·Archiv für Psychiatrie und Nervenkrankheiten·E Metzel, W U Weitbrecht

Administration of MPTP to the common marmoset does not alter cortical cholinergic function

Jan 1, 1986·Movement Disorders : Official Journal of the Movement Disorder Society·J GarveyC D Marsden

On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients

Sep 1, 1972·Journal of Neurochemistry·R Pfeiffer, M Ebadi

Melanin formation by human brain in vitro

Jun 1, 1975·Journal of Neurochemistry·A D Rodgers, G Curzon

Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain

Feb 15, 1973·The New England Journal of Medicine·T L PerryM Kloster

Catecholamines and neurologic diseases (first of two parts)

Aug 7, 1975·The New England Journal of Medicine·M A Moskowitz, R J Wurtman

Synaptic mechanisms in the substantia nigra

Apr 1, 1976·The Journal of Pharmacy and Pharmacology·A Dray, D W Straughan

Parkinson's disease: distribution of Lewy bodies and monoamine neuron system

Apr 26, 1976·Acta Neuropathologica·E Ohama, F Ikuta

The pharmacology of Parkinson's disease: basic aspects and recent advances

Nov 15, 1984·Experientia·M Da PradaW E Haefely

Tetrahydrobiopterin and Parkinson's disease

Jun 1, 1989·Acta Neurologica Scandinavica·I C DissingV Rasmussen

ApoE isoform-specific differences in behavior and cognition associated with subchronic MPTP exposure

Aug 21, 2020·Learning & Memory·Eileen Ruth S TorresJacob Raber

The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain

Jan 1, 1981·Journal of Neural Transmission·G P Reynolds, Peter Riederer

Neurotransmitters and the Lesch-Nyhan syndrome

Nov 5, 1981·The New England Journal of Medicine·Irwin J Kopin

Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake of Glucuronide Metabolites of Androgens

Jun 27, 2020·Molecular Pharmacology·Cindy Yanfei LiBhagwat Prasad

Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism

Jul 1, 1965·Klinische Wochenschrift·H Bernheimer, Oleh Hornykiewicz

Subcortical afferent projection systems in Huntington's chorea

Jan 1, 1989·Acta Neuropathologica·D M Mann

Nerve cell clonal lines in culture--models for studying the molecular basis of neuropharmacological actions

Jan 3, 1983·Klinische Wochenschrift·H Herken

On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease

Apr 2, 1973·Zeitschrift für Neurologie·C CasatiE Dolfini

The association of lesion-induced reductions in brain monoamines with alterations in striatal carbohydrate metabolism

Jan 1, 1973·Journal of Neurochemistry·P C HoffmannA Heller

Autoradiographic localization of dopamine D 1 and D 2 receptors in the brain of several mammalian species

Jan 1, 1990·Journal of Neural Transmission. General Section·M CampsJ M Palacios

Light and electron microscopic autoradiography of substantia nigra of rat after intraventricular administration of tritium labelled norepinephrine, dopamine, serotonin and the precursors

Jan 1, 1971·Zeitschrift für Zellforschung und mikroskopische Anatomie·J ParizekI J Bak

The number of nerve cells in the substantia nigra in paralysis agitans

Nov 18, 1965·Acta Neuropathologica·H Pakkenberg, H Brody

Use of L-dopa in the detection of presymptomatic Huntington's chorea

Jun 22, 1972·The New England Journal of Medicine·H L KlawansA Barbeau

Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor

Jan 1, 1972·Zeitschrift für Neurologie·U K RinneT Sirtola

Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes

Jan 1, 1993·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·H TohgiT Kikuchi

Reversal of the glabellar reflex in Parkinsonism by L-dopa

Oct 1, 1969·Journal of Neurology, Neurosurgery, and Psychiatry·H L Klawans, J A Goodwin

Transitional states of central serotonin receptors in Parkinson's disease

Jan 1, 1981·Journal of Neural Transmission·E KienzlW Wesemann

3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain

Apr 1, 1988·Journal of Neurochemistry·D SchermanYves Agid

Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease

Jan 1, 1993·Journal of Neural Transmission. General Section·J T Greenamyre

Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study

Jan 1, 1997·Journal of Neural Transmission·S SarreY Michotte

Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism

Nov 1, 1985·Acta Neurologica Scandinavica·F Bermejo ParejaJ G de Yébenes

Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms

May 21, 1999·The European Journal of Neuroscience·E BezardC E Gross

Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway

Sep 13, 2001·The European Journal of Neuroscience·Z NiAbdelhamid Benazzouz

Nonhuman primate models of Parkinson's disease

Aug 23, 2007·ILAR Journal·Marina E Emborg

Addiction to apomorphine: a clinical case-centred discussion

Oct 13, 2006·Addiction·Carlos TéllezPablo Venegas

When should levodopa therapy be initiated in patients with Parkinson's disease?

Apr 17, 2007·Drugs & Aging·Irene A C HalkiasHubert H Fernandez

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

Oct 22, 2008·Expert Opinion on Pharmacotherapy·Lawrence W Elmer, John M Bertoni

Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons

Sep 29, 2004·The Journal of Comparative Neurology·Tomás González-HernándezManuel Rodríguez

Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment

Jul 14, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Pauline BelujonAnthony A Grace

Receptor-mediated Parkinson drugs

May 27, 2006·Pharmazie in unserer Zeit·Frank Böckler

Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease

Aug 25, 2004·Drugs & Aging·Dirk DeleuMargaret G Northway

Cell-based therapies for Parkinson's disease: past, present, and future

Jun 3, 2009·Antioxidants & Redox Signaling·Kathleen M FitzpatrickMarina E Emborg

The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats

Nov 10, 2009·Journal of Neurochemistry·Kerstin BuckBoris Ferger

The chlorpromazine enigma

Jan 18, 2013·Journal of the History of the Neurosciences·Alan A Baumeister

Molecular heterogeneity of midbrain dopaminergic neurons--Moving toward single cell resolution

Oct 28, 2015·FEBS Letters·Angela AndereggRajeshwar Awatramani

Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases

Feb 3, 2012·Cellular and Molecular Neurobiology·David S Goldstein

The physiology, signaling, and pharmacology of dopamine receptors

Feb 10, 2011·Pharmacological Reviews·Jean-Martin Beaulieu, Raul R Gainetdinov

Somatostatin antagonist induces catalepsy in the aged rat

Jan 1, 2013·Psychopharmacology·Ilya D Ionov, Irina I Pushinskaya

Levodopa: 50 years of a revolutionary drug for Parkinson disease

Dec 10, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Stanley Fahn, Werner Poewe

Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease

Aug 16, 2016·The European Journal of Neuroscience·Kelly M LohrGary W Miller

Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice

Oct 1, 2017·Scientific Reports·Elsa IsingriniBruno Giros

The Synucleinopathies: Twenty Years On

Mar 12, 2017·Journal of Parkinson's Disease·Michel GoedertMaria Grazia Spillantini

Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence

Sep 1, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Isabelle BoileauStephen J Kish

Selection in the dopamine receptor 2 gene: a candidate SNP study

Aug 21, 2015·PeerJ·Tobias Göllner, Martin Fieder

The premorbid personality of patients with Parkinson's disease: evidence with the Tridimensional Personality Questionnaire

Jan 1, 1995·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·V S KostićN Sternic

Human tyrosine hydroxylase in Parkinson's disease and in related disorders

Jul 12, 2018·Journal of Neural Transmission·T NagatsuKazuto Kobayashi

Lead-Induced Atypical Parkinsonism in Rats: Behavioral, Electrophysiological, and Neurochemical Evidence for a Role of Noradrenaline Depletion

Apr 5, 2018·Frontiers in Neuroscience·Mariam SabbarAbdelhamid Benazzouz

Anschluss 1938: Aftermath on Medicine and Society

Nov 8, 2018·Wiener klinische Wochenschrift·Wolfgang SchützHarald Sitte

Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration

Sep 19, 2017·Nature Neuroscience·Danielle E MorHarry Ischiropoulos

Genetically engineered animal models of Parkinson's disease: From worm to rodent

Dec 16, 2018·The European Journal of Neuroscience·Ludivine S Breger, Marie T Fuzzati Armentero

Zona incerta as a therapeutic target in Parkinson's disease

Aug 4, 2019·Journal of Neurology·Krystyna Ossowska

Imaging SERT Availability in a Rat Model of L-DOPA-Induced Dyskinesia

Aug 9, 2019·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Michael WalkerKristina Herfert

Striatal dopamine deficiency in Parkinson's disease: role of aging

Oct 1, 1989·Annals of Neurology·D SchermanY Agid

The hypothalamus in Parkinson's disease

Apr 1, 1987·The International Journal of Neuroscience·R Sandyk, R P Iacono

The biochemistry of the basal ganglia and Parkinson's disease

Dec 1, 1977·Postgraduate Medical Journal·G Curzon

Postmortem changes in binding to the muscarinic receptor from human cerebral cortex

Jul 1, 1983·Journal of Neurochemistry·A UndénT Bartfai

Homovanillic acid and dihydroxyphenylacetic acid in the striatum of monkeys with brain lesions

Jan 1, 1967·Canadian Journal of Physiology and Pharmacology·D F SharmanT L SOURKES

Levodopa and relief of Parkinsonian symptoms

Mar 1, 1971·Arquivos de neuro-psiquiatria·R P Schmidt, M Greer

Modification of the tremorigenic activity of physostigmine

Oct 1, 1972·British Journal of Pharmacology·L M Ambrani, M H Van Woert

The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism

Jan 1, 1990·Drug Metabolism Reviews·G MaretP A Carrupt

Clinical analyses of factors influencing L-dopa treatment of Parkinson's syndrome

Jul 1, 1972·Acta Medica Scandinavica·A K GranerusA Svanborg

Cerebrospinal fluid choline in extrapyramidal disorders

Oct 1, 1972·Journal of Neurology, Neurosurgery, and Psychiatry·S M AquiloniusA Sundwall

Quantitative study of the effect of L-dopa and phenoxybenzamine on the rigidity of Parkinson's disease

Jun 1, 1973·Journal of Neurology, Neurosurgery, and Psychiatry·C J Andrews, D Burke

Effect of L-DOPA on brain concentration of dopamine and homovanillic acid in rats after chronic manganese chloride administration

Feb 1, 1974·Journal of Neurochemistry·E Bonilla, M Diez-Ewald

Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis

Jan 1, 1994·Journal of Neurochemistry·J A TemlettG W Grime

Amine accumulation: a possible precursor of Lewy body formation in Parkinson's disease

Sep 1, 1992·The International Journal of Neuroscience·R Sandyk, G L Willis

The antagonism between reserpine and some antiparkinson drugs in electroseizure

Jan 1, 1968·Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie·I Jurna, B Regélhy

Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease

Jul 2, 2003·Neurotoxicity Research·Manfred GerlachPeter Riederer

EXCRETION OF DOPAMINE, CATECHOLAMINE METABOLITES AND 5-HYDROXYINDOLEACETIC ACID IN HEPATOLENTICULAR DEGENERATION (WILSON'S DISEASE)

Dec 1, 1963·Journal of Neurochemistry·T L SOURKESS SAINTCYR

Fetal tissue transplantation for patients with Parkinson's disease: a database of published clinical results

Dec 12, 2001·Drugs & Aging·E D Clarkson

Experimental models of Parkinson's disease: from the static to the dynamic

Aug 26, 1998·Reviews in the Neurosciences·Erwan BezardC E Gross

Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum

Oct 11, 2003·Journal of Neurochemistry·John W HaycockStephen J Kish

THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY

Jun 1, 1964·Archiv für Psychiatrie und Nervenkrankheiten·W UMBACH, D BAUMANN

Functional models of Parkinson's disease: a valuable tool in the development of novel therapies

Jan 8, 2009·Annals of Neurology·Peter Jenner

Manganese and Parkinson's disease: a critical review and new findings

Apr 21, 2010·Environmental Health Perspectives·Tomás R Guilarte

LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function

Jan 9, 2016·Human Molecular Genetics·Max SloanRichard Wade-Martins

Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness

Mar 7, 2008·Neuro-degenerative Diseases·Oleh Hornykiewicz

A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease

May 23, 2014·Journal of Neurochemistry·David S GoldsteinIrwin J Kopin

Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside

Mar 10, 2017·Upsala Journal of Medical Sciences·Sten-Magnus Aquilonius, Dag Nyholm

Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence

Aug 16, 2016·The European Journal of Neuroscience·Stephen J KishJunchao Tong

Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota

Jun 21, 2015·Journal of Neurovirology·Sylvia M DobbsIngvar T Bjarnason

Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects

Sep 20, 2016·Scientific Reports·Laurence BorgsLaurent Nguyen

Dopamine, Oxidative Stress and Protein-Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases

Dec 12, 2018·Angewandte Chemie·Enrico MonzaniLuigi Casella

Antiarrhythmics cure brain arrhythmia: The imperativeness of subthalamic ERG K+ channels in parkinsonian discharges

May 17, 2017·Science Advances·Chen-Syuan HuangYa-Chin Yang

Dopamine-sensitive adenylate cyclase activity in the striatum in Parkinson's disease

Jan 1, 1979·Journal of Neural Transmission·M Shibuya

Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients

Jan 1, 1985·Journal of Neural Transmission·M SawadaH Narabayashi

Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines

Jul 7, 2006·Cellular and Molecular Neurobiology·Toshi Nagatsu, Makoto Sawada

Neuroprotection in Parkinson's disease: a realistic goal?

Nov 11, 2010·CNS Neuroscience & Therapeutics·Salvatore Galati, Giuseppe Di Giovanni

Partial lesion of the dopaminergic innervation of the ventral striatum induces "depressive-like" behavior of rats

Feb 24, 2012·Pharmacological Reports : PR·Katarzyna KuterKrystyna Ossowska

Helicobacter hypothesis for idiopathic parkinsonism: before and beyond

Mar 3, 2009·Helicobacter·R John DobbsJohn Williams

Diagnosing Parkinson Disease

Aug 9, 2016·Continuum : Lifelong Learning in Neurology·Christopher W Hess, Michael S Okun

Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease

Apr 13, 2018·NPJ Parkinson's Disease·David SulzerLuigi Zecca

Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP

Nov 1, 1990·The Journal of Pharmacy and Pharmacology·C RamassamyJ Costentin

Weak magnetic fields as a novel therapeutic modality in Parkinson's disease

Sep 1, 1992·The International Journal of Neuroscience·R Sandyk

Release from brain tissue of compounds with possible transmitter function: interaction of drugs with these substances

Oct 1, 1969·British Journal of Pharmacology·M Vogt

Interference with the fluorometric assay for homovanillic acid caused by acid metabolites of catecholamines

Dec 1, 1972·Journal of Neurochemistry·G J KirschbergS Ginsburg

Various mental behavioral disorders in Parkinson's disease, primary degenerative senile dementia, and multiple infarction dementia

Jan 1, 1983·Journal of Neural Transmission·W Danielczyk

EVIDENCE FOR A ROLE OF DOPAMINE IN EXTRAPYRAMIDAL FUNCTIONS

Oct 2, 1964·Acta Neurovegetativa·A CARLSSON

NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES

Jan 1, 1964·Acta Psychiatrica Scandinavica·A FaurbyeH Pakkenberg

Saskatchewan movement disorders program

Mar 26, 2015·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Ali H Rajput, Alex Rajput

The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication

Nov 13, 2014·Frontiers in Cellular Neuroscience·Mohamed OuzzineSylvie Fournel-Gigleux

Is art therapy a reliable tool for rehabilitating people suffering from brain/mental diseases?

Apr 8, 2015·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Giovanni Mirabella

Treatment of parkinsonism with L-dopa

Dec 1, 1971·Arquivos de neuro-psiquiatria·R Melaragno, G M Karam

Concentrations of dopamine and noradrenaline in some limbic and related regions of the human brain

Apr 1, 1982·Acta Neurologica Scandinavica·P NybergB Winblad

Juvenile Parkinsonism

Jun 1, 1972·Developmental Medicine and Child Neurology·E M Brett

The scientific basis for the current treatment of Parkinson's disease

Jan 30, 2004·Annual Review of Medicine·C Warren Olanow

Determination of reactive oxygen species associated with the degeneration of dopaminergic neurons during dopamine metabolism

Dec 18, 2009·Free Radical Research·Mayumi YamatoHideo Utsumi

Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems

Dec 17, 2009·Journal of Cellular Biochemistry·Dong-Youn HwangDong-Wook Kim

Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease

Oct 15, 2010·Nature Reviews. Neuroscience·Peter RedgraveJose A Obeso

Fifty years of Parkinson's disease: one step forwards, two steps back?

Oct 11, 2016·British Journal of Hospital Medicine·Simon Jg Lewis

Animal Models of Parkinson's Disease: Are They Useful or Not?

Jul 28, 2020·Journal of Parkinson's Disease·Roger A Barker, Anders Björklund

Adult Endogenous Dopaminergic Neuroregeneration Against Parkinson's Disease: Ideal Animal Models?

Nov 4, 2020·Neurotoxicity Research·Yuganthini VijayanathanKalavathy Ramasamy

Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse

Dec 2, 2020·The American Journal of Psychiatry·Joseph T CoyleDarrick T Balu

Evolution of in vivo dopamine monitoring techniques

Dec 6, 2020·Pharmacology, Biochemistry, and Behavior·Alyssa G Yocky, Dan P Covey

D1 , not D2 , dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopa

Dec 7, 2020·European Journal of Pharmacology·Richard B MailmanXuemei Huang

The hidden side of Parkinson's disease: Studying pain, anxiety and depression in animal models

Oct 27, 2018·Neuroscience and Biobehavioral Reviews·Fanny FaivreMichel Barrot

Related Concepts

Brain Chemistry

Catecholamines

Extrapyramidal Tract

Trending Feeds

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.